NCT03980912View on ClinicalTrials.gov

Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy

WithdrawnOBSERVATIONAL
0
Timeline

Start Date

September 1, 2019

Primary Completion Date

September 1, 2020

Study Completion Date

November 1, 2020

Conditions
NAFLDNASH
Interventions
DIAGNOSTIC_TEST

LiverFASt

LiverFASt™ is a blood based diagnostic test utilizing a patented algorithm to determine presence and the progression of liver disease. The test is non-invasive, simple, and less expensive than liver biopsy or liver imaging.

Trial Locations (1)

32817

ObvioHealth, Orlando

Sponsors
All Listed Sponsors
collaborator

OBVIO HEALTH USA, Inc.

UNKNOWN

lead

Fibronostics USA, Inc

OTHER

NCT03980912 - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy | Biotech Hunter | Biotech Hunter